News from the Beijing News (Reporter Zhang Zhaohui) On February 25, Haisco issued an announcement saying that the wholly-owned subsidiary Liaoning Haisco product Cyclopofol Injection (20ml, 50mg) added the adaptation of “general anesthesia induction and maintenance” disease, approved by the State Food and Drug Administration.
Cyclopofol injection is an intravenous anesthetic, and its active ingredient, cyclopofol, is a small molecule drug with (R)-configuration isomer, and is a GABAA receptor agonist. Mediated chloride channels, increase current conduction, causing neuronal hyperpolarization. This hyperpolarization causes consistent neural signal transmission and reduces the success rate of action potential generation, thereby depressing the central nervous system and producing anesthesia.
Hisco disclosed that the product has good overall safety and tolerance, and its efficacy and activity is about 5 times that of propofol. The effect on respiration is better than that of propofol, the effect on heart rate and blood pressure is not inferior to that of propofol, and the lipid input is less than that of propofol.
Cyclopofol injection has been approved by the State Food and Drug Administration for the following indications: “Sedation during gastrointestinal endoscopy”, “Sedation during bronchoscopy” and “Induction and maintenance of general anesthesia” , “Sedation during intensive care” and “Sedation and anesthesia for gynecological outpatient surgery” are still in the approval process of the marketing application.
Hisco said that the new indication “induction and maintenance of general anesthesia” has been approved for marketing, which will further expand the clinical application market of cyclopofol injection.
Proofreading by Chen Diyan